Skip to main content
. Author manuscript; available in PMC: 2008 Oct 22.
Published in final edited form as: Neuroscience. 2008 Feb 15;153(1):329–337. doi: 10.1016/j.neuroscience.2008.02.004

Figure 2.

Figure 2

Ceftriaxone attenuates the R6/2 behavioral phenotype as measured in the plus maze and open-field. A, R6/2 mice treated with ceftriaxone made significantly more turns in the plus-maze than saline-treated R6/2 mice on post-treatment day 1, and did not differ from WT mice on both post-treatment days (n = 9 for WT saline and ceftriaxone, n = 5 for R6/2 saline, n = 7 for R6/2 ceftriaxone). B, R6/2 mice treated with ceftriaxone engaged in climbing more than saline treated R6/2 mice on post-treatment day 1, and did not differ from WT mice on both post-treatment days. Saline treated R6/2 mice climbed less than WT mice on both post-treatment days. C, Treatment with ceftriaxone attenuated expression of the twitching phenotype in R6/2 mice on post-treatment day 7 (n= 9 for WT saline, WT ceftriaxone, and R6/2 ceftriaxone, n = 8 for R6/2 saline). *p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SEM.